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Abstract
Background: Changes of life expectancy over time serve as an interesting public health indicator for medical,
social and economic developments within populations. The aim of this study was to quantify changes of life
expectancy between 1950 and 2010 and relate these to main causes of death.
Methods: Pollard’s actuarial method of decomposing life expectancy was applied to compare the contributions of
different age- and disease-groups on life expectancy in 5-year intervals.
Results: From the 1960 to 70s on, declines in cardiovascular disease (CVD) mortality play an increasing role in
improving life expectancy in many developed countries. During the past decades gains in life expectancy in these
countries were mainly observed in age groups ≥65 years. A further consistent pattern was that life expectancy
increases were stronger in men than in women, although life expectancy is still higher in women. In Japan, an
accelerated epidemiologic transition in causes of death was found, with the highest increases between 1950 and
1955. Short-term declines and subsequent gains in life expectancy were observed in Eastern Europe and the former
states of the Union of Soviet Socialist Republics (USSR), reflecting the changes of the political system.
Conclusions: Changes of life years estimated with the decomposing method can be directly interpreted and may
therefore be useful in public health communication. The development within specific countries is highly sensitive
to changes in the political, social and public health environment.
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Introduction
Since 1840, life expectancy of the best performing coun-
try in each year has been increasing almost linearly by
2.5 years per decade [1]. Japan achieved the world’s high-
est life expectancy over the past 50 years, starting from a
very low level at the end of World War II [1, 2], while
Japan’s health expenditures are relatively low compared
to other nations [2].
From a conceptual perspective, the development of
mortality in populations follows similar patterns. The
epidemiological transition theory states that when na-
tions improve their economic situation, communicable
diseases like infectious and parasitic diseases will be re-
placed by non-communicable diseases like cardiovascu-
lar diseases (CVD) and cancer [3, 4]. However, the speed
of development is affected by various factors. The large
variations can be attributed to different economic situa-
tions, nutritional and lifestyle factors, work-related and
social factors, as well as public health strategies and
medical care [5]. In order to set up sound public health
programs for healthy aging, it is important to know
which causes of death and which age groups harbor the
greatest potential for improving life expectancy.
Since 1950, the World Health Organization (WHO)
has been collecting data on mortality and causes of
death. Life expectancy is a convenient and important
summary measure of mortality, and more intuitive than
mortality rates. The method suggested by Pollard esti-
mates the absolute contribution of each cause of death
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and each age group expressed as life years to the change
of life expectancy [6]. This measure can serve as an in-
teresting indicator for social and economic develop-
ments within a population. An advantage of this method
is that the results can be directly interpreted as changes
of life years, and may therefore be used directly in public
health communication.
The objectives of this study were to give a longitudinal
overview of the contributions of age- and disease-specific
mortality rates to the changes in life expectancy, as exem-
plified and presented for selected countries between 1950
and 2010.
Material and methods
Database
The mortality database of the World Health Organization
(WHO) was used for the present analyses (date of ex-
traction: December 2013) [7], comprising sex-, age-
and disease-specific deaths, as well as corresponding
population numbers registered in national civil regis-
tration systems from 123 countries for each calendar
year between 1950 and 2011. During the reporting
period some countries were divided (e.g., Yugoslavia) or
unified (e.g., Germany). Since data were not continuously
available for all countries or for the entire observation
period, gaps in the timeline exist. In the current analysis
only sovereign states with time intervals of continuous
data reporting over at least 10 years were considered to
produce more robust estimates (n = 77). Countries with
reporting periods ending before 1990 were excluded as
well as those with a total average population of less than
one million to reduce random effects due to small num-
bers of death. Finally, data from 64 countries were ana-
lyzed. We further selected five countries with high life
expectancy but varying health expenditures for in-depth
analyses: Japan, Switzerland, Singapore, Germany and the
US (Table 1). Overall, the data quality and completeness
of the included death registers are very heterogeneous [8].
In 2003 more than 80 % had a completeness of 100 %,
while 12 % had less than 90 % completeness, with a mini-
mum of 54 % in China [8]. The proportion of deaths
coded to ill-defined codes ranged from 3 % in Singapore
and Finland to 26 % in Greece. In all of the five selected
countries, however, the completeness was 100 %, with the
proportion of deaths coded to ill-defined codes ranging
from 3 to 14 %.
Disease-specific causes of death were reported according
to the International Classification of Diseases (ICD).
During the observation period four versions of the
ICD were used (1962–1968: ICD 7, 1969–1978: ICD 8,
1979–1997: ICD 9 and 1998–2011: ICD 10), which were
transferred to ICD 10. To handle coding imprecision,
and to have a sufficient number of deaths even for small
countries, only main disease groups were considered. The
selected causes of mortality account for more than 90 %
of all recorded deaths: infectious and parasitic diseases
(ICD 10: A00-B99), malignant neoplasms (C00-C97), dis-
eases of the circulatory system (I00-I99), diseases of the
respiratory system (J00-J99), diseases of the digestive sys-
tem (K00-K93), perinatal diseases (P00-P96) and external
causes of mortality (V01-Y98). All other causes of death
were combined as “other diseases”.
Analysis
An actuarial method of decomposing life expectancy
was used to estimate the contributions of different age
groups and disease-specific causes of death to the changes
in life expectancy [9]. This method proposed by Pollard
was selected because it allows for simultaneously decom-
posing both different age groups and different causes of
death. It is also nonparametric, avoiding strong model
assumptions. Furthermore, the method has a simple and
intuitive output, and refrains from splitting effects into
different subtypes. For example, it is possible to calculate
that the contribution of the reduction in cardiovascular
mortality to the increased life expectancy in Japanese
women between 2000 and 2005 was 0.47 years. Consider-
ing the cause-specific mortality difference in every single
age group within a specific time interval (e.g., 1 year), the
difference Δ in average life expectancy at birth between
two points in time, denoted in the following by a super-
script 1 or 2, is given by the formula:
Δ2−1 ¼ e20−e10 ¼
Xn
i¼1
Xω
x¼0
iQ
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x−iQ
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 
⋅wxwithwx
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where ex
1 and ex
2 are the life expectancies at age x for spe-
cific points in time 1 and 2; n denotes the number of
considered causes of death and ω the last included age
interval; iQx is the mortality rate of the i-th cause of
death at age interval x with the weight wx. xp0
1 and xp0
2
denoting the probability of living from birth to age x at
time point 1 and 2 derived from the corresponding life
tables. Since mortality rates in the WHO database were
reported for 5-year age groups the equation had to be
adapted accordingly. To adjust for short-term variability,
a weighted moving average technique was applied to
mortality rates and population numbers [10]. The width
of the moving window was 3 years.
For every country the age- and disease-specific change
in life expectancy was calculated for adjacent time inter-
vals of 5 years starting in 1950 and ending in 2010
(1950–55, 1955–1960, …, 2005–2010) if continuous
mortality and population data were available for the spe-
cific interval. The age-specific change in life expectancy
was reported in five categories: 0–4, 5–14, 15–39, 40–64
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Table 1 Characteristics of selected countries
Country Observation
period
Total
populationa
Life
expectancy
womena, b
Life
expectancy
mena,b
Gross national
income per
capita (US$)a, b
Total health
expenditure per
capita (int $)a, b, c
Total health expenditure
as % of gross domestic
producta, b
Japan 1950–2010 127,450,459 86.3 79.6 42,190 3,237 9.6
Hong Kong SAR 1960–2010 7,024,200 86.0 80.1 33,620 NA NA
France 1955–2005 65,023,142 85.3 78.2 43,790 4,039 11.7
Italy 1955–2000 59,277,417 85.0 79.8 37,690 3,162 9.4
Spain 1955–2010 46,576,897 84.7 78.7 32,130 3,026 9.6
Switzerland 1955–2010 7,824,909 84.5 80.1 77,360 5,319 10.9
Republic of Korea 1985–2010 49,410,366 84.1 77.2 21,320 2,069 7.3
Australia 1950–2000 22,031,800 84.0 79.5 46,490 3,761 8.9
Singapore 1965–2010 5,076,700 84.0 79.2 44,790 2,773 4.1
Israel 1975–2010 7,623,600 83.6 79.7 29,480 2,078 7.6
Sweden 1955–2010 9,378,126 83.5 79.5 53,810 3,762 9.5
Norway 1955–2010 4,889,252 83.2 78.9 86,830 5,475 10.0
Canada 1950–2005 34,005,274 83.2 78.7 44,450 4,468 11.4
Austria 1995–2010 8,389,771 83.2 77.7 49,180 4,517 11.6
Finland 1955–2010 5,363,352 83.2 76.7 49,320 3,297 9.0
Ireland 1950–2005 4,560,155 83.1 78.5 43,760 3,796 9.3
Greece 1965–2010 11,153,454 83.0 77.9 27,580 2,685 9.4
Belgium 1955–1995 10,920,272 83.0 77.6 47,200 4,058 10.5
Netherlands 1950–2010 16,615,394 82.7 78.8 53,320 5,063 12.1
New Zealand 1950–2005 4,367,800 82.7 78.8 28,980 3,034 10.2
Slovenia 1985–2010 2,048,583 82.7 76.3 24,540 2,452 8.9
Germany, Former Federal
Republic
1955–1990 1990: 63,253,800 1989: 78.6 1989: 72.1 1990: 20,630 NA NA
Germany 1990–2010 81,776,930 82.6 77.5 44,780 4,426 11.5
United Kingdom 1950–2010 62,766,365 82.4 78.5 40,470 3,223 9.6
Chile 1955–1990 17,150,760 82.1 76.2 10,730 1,309 7.1
Portugal 1955–2000 10,573,100 82.1 76.1 22,930 2,810 10.8
Puerto Rico 1970–1990 3,721,208 82.1 74.4 16,650 NA NA
Costa Rica 1965–1995 4,669,685 81.7 77.0 6,910 1,167 9.7
Denmark 1955–2005 5,547,683 81.2 77.1 60,820 4,545 11.1
United States of America 1950–2005 309,326,295 81.0 76.2 49,110 8,299 17.7
Cuba 1970–1995 11,281,768 80.8 76.7 5,630 1,823 10.6
Czechoslovakia, Former 1955–1990 1991: 15,592,000 NA NA NA NA NA
Czech Republic 1990–2010 10,474,410 80.6 74.4 19,210 1,930 7.4
Slovakia 1995–2010 5,391,428 78.8 71.6 17,130 2,039 9.0
Poland 1960–2010 38,183,683 80.6 72.1 12,580 1,432 7.0
Estonia 1985–2010 1,331,475 80.5 70.6 14,390 1,300 6.3
Uruguay 1955–1990 3,371,982 80.2 73.2 10,110 1,423 8.7
Yugoslavia, Former 1965–1990 1990: 23,817,900 NA NA NA NA NA
Croatia 1985–2010 4,417,781 79.6 73.5 13,740 1,607 7.8
Serbia 2000–2010 7,291,436 76.6 71.4 5,850 1,191 10.7
Argentina 1980–1995 40,374,224 79.5 72.0 2005: 4,450 1,312 8.2
Mexico 1960–1995 117,886,404 79.2 74.3 8,730 1,003 6.3
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and ≥65 years. As indicators for the epidemiological
transition, time intervals where highlighted by different
colors in Tables 2 and 3 if the highest contribution to life
expectancy was due to cardiovascular diseases (green),
the age group ≥65 years (blue) or both (red). This con-
tribution had to be present for at least two subsequent
time intervals with not more than one gap between the
intervals. All calculations were performed using SAS 9.2.
Results
The characteristics of the selected countries referenced
for 2010 and sorted by life expectancy are presented in
Table 1. According to the classification of the United
Nations, 36 countries were from Europe, 14 from Asia,
nine from Latin America and the Caribbean, two from
North America, two from Oceania and one from Africa.
Life expectancy for women ranged from 69.3 years in
Turkmenistan to 86.3 years in Japan and for men from
60.9 years in Turkmenistan to 80.1 years in Hong Kong
and Switzerland. The lowest Gross National Income
(GNI) per capita was reported in Tajikistan (US$730) and
the highest in Norway (US$86,830). Total expenditures on
health in relation to GNI varied considerably between
countries. For example in Singapore, Japan, Switzerland,
Germany and the US 4.1, 9.6, 10.9, 11.5 and 17.7 % were
reported, respectively. In contrast, differences in life ex-
pectancy between these countries were less pronounced,
with the US trailing behind.
In most of the investigated countries positive values of
the relative change in life expectancy by 5-year intervals
were observed in women (Table 2) and men (Table 3) in-
dicating an increase in life expectancy. Extremely posi-
tive changes in life expectancy were observed in Japan
between 1950 and 1955: for men and women the overall
increase in life expectancy was 4.8 and 5.7 years, respect-
ively. Tremendously negative changes were seen among
men and women (relative decline −5.2 and −2.6 years,
respectively) in the former Soviet Union between 1990
and 1995, while life expectancy increased afterwards. In
Germany life expectancy increased since the 1970s be-
tween around 1–2 years per 5-year time interval in both
men and women. Although in most of the developed
countries female life expectancy is still higher than male
life expectancy, the increase in life expectancy was sharper
Table 1 Characteristics of selected countries (Continued)
Lithuania 1985–2010 3,097,282 78.8 68.0 12,260 1,387 7.0
Latvia 1980–2010 2,097,555 78.4 68.8 12,680 1,145 6.5
Hungary 1955–2010 10,000,023 78.1 70.5 13,050 1,701 8.0
Armenia 1985–2000 2,963,496 77.7 70.9 3,370 291 4.6
Romania 1970–2010 20,246,871 77.3 69.8 8,430 964 5.9
Venezuela 1955–1990 29,043,283 77.2 71.3 11,520 795 4.7
Bulgaria 1965–2010 7,395,599 77.2 70.0 6,630 1,088 7.6
TFYR Macedonia 1995–2010 2,102,216 77.0 72.5 4,570 778 7.0
Mauritius 1965–2005 1,280,924 76.7 69.5 7,780 813 5.4
Belarus 1985–1995 9,490,000 76.5 64.6 5,990 855 5.6
China,select urban and
rural areas
1990–2000 1,337,705,000 76.2 73.6 4,240 441 5.0
Ukraine 1985–2005 45,870,700 75.5 65.3 2,990 599 7.8
Kuwait 1975–2000 2,991,580 75.1 73.2 42,920 2,286 2.8
Russian Federation 1980–2010 142,385,523 74.9 63.1 10,010 1,410 6.3
Azerbaijan 1985–2000 9,054,332 73.6 67.4 5,370 831 5.3
Kyrgyzstan 1985–2005 5,447,900 73.5 65.3 850 186 6.7
Trinidad and Tobago 1970–1990 1,328,095 73.3 66.1 15,800 1,494 5.2
Kazakhstan 1985–2010 16,321,581 73.3 63.5 7,440 871 4.3
Republic of Moldova 1985–2010 3,562,045 72.4 64.7 1,820 448 11.7
Uzbekistan 1985–2005 28,562,400 71.3 64.6 1,300 226 5.4
Tajikistan 1985–2000 7,627,326 70.4 63.8 730 125 6.0
Turkmenistan 1985–1995 5,041,995 69.3 60.9 4,070 196 2.1
Countries with high life expectancy but varying health expenditures who were selected for in-depth analyses are highlighted in bold text
aData from the year 2010 unless otherwise noted
bData from World Bank
cHealth expenditure per capita in international $ considering country-specific purchasing power parity (PPP) rates
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in men during the last decades. This, however, was not
true for Japan.
As examples for different developments in life expect-
ancies among countries with high life expectancy we
present the cause- and age-group-specific data of Japan,
Switzerland, Singapore, Germany and the US for women
(Fig. 1) and men (Fig. 2) in order to explore differences.
Particular patterns will be highlighted. In Japan after
World War II the increase in life expectancy was excep-
tionally marked until 1965. Successively the contribution
of the oldest age group increased, becoming dominant
after 1965. Switzerland reached its comparably high life
expectancy with a different more monotonic pattern.
CVD was the most important contributor across the
whole observation period. Even in the last period from
2005 to 2010 the relative contribution of CVD to the
change in life expectancy was remarkable. In Japan, the
United States, Germany, Singapore and Switzerland the
contributions of CVD for women were 94, 78, 75, 61,
58 % and for men 67, 73, 59, 49, 48 %, respectively.
Table 2 Overall change in life expectancy [years] by 5-year interval in women
Green: cardiovascular diseases are the most important cause contributor but age group 65 years and older is NOT the most important age contributor, blue: age
group 65 years and older is the most important age contributor but cardiovascular diseases are NOT the most important cause contributor, red: cardiovascular
diseases are the most important cause contributor AND age group 65 years and older is the most important age contributor
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In Germany, a remarkable relapse in the develop-
ment of life expectancy was observed in men and
women between 1965 and 1970. During the fall of
the Iron Curtain only a small effect on German life
expectancy was seen. In contrast, a tremendous de-
crease in life expectancy was observed for Russian
men and to a lesser extent for women between 1990
and 1995. Mortality increased mainly in persons aged
15–64 years, and was due to CVD and external
causes. During the past decades this was counterba-
lanced by increases in life expectancy. In the US, the
patterns of changes in life expectancy were heteroge-
neous, with highest increases in life expectancy in the
1970s mainly due to CVD. The patterns observed in
Singapore suggest a delayed epidemiological transi-
tion, with increasing contributions of CVD since
1980. In the following 30 years the increase in life ex-
pectancy was particularly high with an increase of
more than 10 life years in men and women. Starting
in the 1990s, a decline in mortality due to malignant
neoplasms led to a small but notable contribution to
the increase in life expectancy.
Table 3 Overall change in life expectancy [years] by 5-year interval in men
Green: cardiovascular diseases are the most important cause contributor but age group 65 years and older is NOT the most important age contributor, blue: age
group 65 years and older is the most important age contributor but cardiovascular diseases are NOT the most important cause contributor, red: cardiovascular
diseases are the most important cause contributor AND age group 65 years and older is the most important age contributor
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Considering age- and disease-specific contributions to
life expectancy for the investigated countries some basic
patterns could be identified (see Tables 2 and 3, as well
as Additional file 1: Tables S1–S4). In women (Table 2)
declining cardiovascular disease death rates, often in com-
bination with changes in the highest age group (red color),
became the dominant cause for reductions in all-cause
mortality in the 1950s and 60s for North America, most
western European countries and for Japan, Australia and
New Zealand. After the fall of the Iron Curtain in the
1990s, the same pattern was seen for most of the future
members of the European Union (e.g., Hungary) but not
for all (e.g., Poland).
The contribution of the age group 65 years and older
to the change in life expectancy was dominant already in
the 1950s in a few Western European countries and
Australia. Corresponding to the cause of death specific
development, this age group (≥65 years) gained import-
ance in the following years for more and more countries.
For men, the development of the age- and cause-specific
contributions was similar, but in most countries was de-
layed for up to two decades (e.g., France). In the time
period 1990–1995, directly after the fall of the Iron
Curtain, a remarkably steep decrease of life expectancy
was seen in the age groups “40–64 years” and “65 years
and over” in all countries of the former USSR. The de-
crease was strongest in Russian men with a loss of 5.2
life years within this 5-year interval.
Discussion
Starting in the early 1960s and 1970s CVD mortality de-
clines played an increasing role in improving life expect-
ancy in many Western European countries as well as in
Japan, Singapore, Australia, New Zealand and the United
States. In these countries gains in life expectancy during
the past decades were mainly observed in age groups
≥65 years particularly in women. The development for
men was delayed for up to two decades compared to
women. In Japan, an accelerated epidemiologic transition
in causes of death from infectious and respiratory to
CVD and from young age-groups to older age groups
was found. In Eastern Europe, Russia and some other
former states of the Union of Soviet Socialist Republics,
Fig. 1 Five-year contribution of different age- and disease-groups to the changes in life expectancy in women between 1950 and 2010 in Japan,
Switzerland, Singapore, Germany and the United States
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periods with declines in life expectancy particularly in
men were observed.
Compared to population-based morbidity data, life
expectancy at birth as a measure of mortality is a valid
and important indicator of a population’s health status.
It is easy to interpret and is intuitive for both layman
and experts. The method of decomposing total life
expectancy with respect to age- and disease-specific
contributions is commonly used in demographical but
rarely in public health and epidemiological research.
However, this approach allows translating the immediate
influence of changes in lifestyle as well as socio-
economic and political living conditions on mortality
rates into age- and disease-specific contributions to
short-term changes in life expectancy.
Limitations of our study are related to data gaps con-
cerning completeness and information of causes of death
which may have affected some of the observed differences
[8]. Causes of death have been coded using varying ICD
versions [7–10]. Therefore, code conversion was necessary,
which may have resulted in some conversion imprecision.
Differences in the application of the classification of causes
of death could have introduced bias as well. However,
using only main disease-groups should have reduced bias
to a minimum. The completeness and reporting quality
differed between countries [8]. Many countries were ex-
cluded due to missing long-term data. In some of the
analyzed countries and time intervals the proportion of
deaths coded as ‘symptoms, signs and abnormal clinical
and laboratory findings’ is high and could have intro-
duced bias. Due to the structure of the WHO Mortality
Database, it was not possible to redistribute these
deaths to specific causes. This may underestimate the
true contribution of a specific cause of death and in-
crease the contribution of “others”.
Gender differences in life expectancy are present in all
countries. For example, in Japan the absolute number
was 6.7 years in 2010. The mortality rates at older ages
decreased faster in women than in men [11, 12]. Gender
differences in CVD mortality vary over time and geo-
graphically [13]. It has been suggested that the difference
in life expectancy between men and women could be
partly related to biological factors [14]. A greater differ-
ence is thought to be related to environmental factors
Fig. 2 Five-year contribution of different age- and disease-groups to the changes in life expectancy in men between 1950 and 2010 in Japan,
Switzerland, Singapore, Germany and the United States
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[13]. Also gender-related factors such as risky behavior
of men and differences in body size, hormonal factors
and innate immunity could contribute to the observed
differences in human mortality [15, 16]. The lower CVD
mortality in women [17] can be explained by differences
in diet and lifestyle factors [18].
The epidemiological transition provides the theoretical
background for the massive improvement in life expect-
ancy during the 20th century [4]. The stage of the epi-
demiological transition differed between countries. The
transition from communicable to non-communicable
diseases as the main causes of deaths marks a new phase
in the mortality development. Today, most premature
deaths are preventable, and a major part are attributed
to non-communicable disease (NCD), mainly heart dis-
ease, stroke, cancer, diabetes and chronic respiratory dis-
eases [19]. Since the 1980s several criticisms of the
epidemiological transition have been brought forward,
since it requires morbidity and mortality data over long
time periods. These data are often lacking in middle- and
low-income countries. Therefore, it is important to pro-
mote and establish systematic health reporting especially
in those countries.
The developments in Japan since World War II illus-
trate the concept of epidemiological transition within a
very short time period. Since 1986 Japan has ranked first
for female life expectancy, with the worldwide highest
life expectancy of 86.3 years in 2010 [20]. Substantial
gains in longevity occurred between 1950 and 1965 by
the reduction of infant and young adult mortality. The
control of intestinal and respiratory infection, and the
implementation of vaccination programs may have
contributed to this development [2, 21]. When commu-
nicable diseases had been controlled in the seventies, life
expectancy continued to rise due to declines in mortality
from NCDs.
With regard to recent evaluations of the health care
system, medical care as well as total expenditures on
health in Japan seem to be average [2]. However, the
interplay between general favorable risk factors, the
country’s educational profile and broad prevention pro-
grams with universal coverage based on strong govern-
ment action may explain why life expectancy in Japan
increased so rapidly and keeps this leading position
compared to other countries with much larger total ex-
penditure on health care like the US [22]. Traditionally,
the Japanese diet is rich in rice, salt, soy and fish intake,
and low in fat intake. With regard to high salt consump-
tion, especially in Northern Japan, public health pro-
grams were developed and hypertension was targeted
and treated as a major public health problem [2].
Our observation that among women CVD mortality
declines became the most prominent cause for reductions
in all-cause mortality in 1950s and 1960s in many
industrialized countries is consistent with other reports
and clearly shows the effectiveness of prevention programs
related to smoking behavior, alcohol consumption and
physical activity as well as improved treatment [23–25].
However, some of these changes might have been due to
infectious diseases and other sources of inflammation [26].
An example to the contrary is Russia’s extreme drop in
life expectancy after 1990. The rise in mortality between
1990 and 1995, particularly in young-middle aged men,
has been attributed to the economic and social instabil-
ity during that period, which may have caused stress,
anxiety and depression [27]. After 1995 life expectancy
in Russia for both genders improved, with a sharp in-
crease between 2005 and 2010. Germany after its unifi-
cation showed the opposite development. After adapting
to the living conditions of Western Germany, life expect-
ancy of people in former Eastern Germany increased by
3.2 years within a period of just 7 years [28].
The small gains in life expectancy in the US in recent
years may be partly due to the high prevalence of obesity
[29]. In addition, social inequalities are likely to result in
ineffective prevention and health-care interventions. The
systems of countries like Japan and Sweden, which have
less social inequality and more equal access to the med-
ical system and treatment, are likely to be more effective
at increasing life expectancy [30].
Global key actions to reduce the burden of NCD have
been identified by the WHO [31]. The WHO has proposed
a 25 % reduction of NCD mortality by 2025. Modifiable
risk-factors for NCDs have been identified, and there is evi-
dence at the individual and population level that large-
scale prevention has the potential to lower the individual
disease burden and to save lives [32]. The prevention of
NCDs has been ranked a top global priority for economic
development [31]. For countries with high health expendi-
tures like the US, Germany and other countries of central
Europe, the implementation of acceptable cost-effective
multi-sectorial prevention programs on tobacco control
and salt reduction, as well as the promotion of healthy diet
and physical activity, are suitable to handle and contain
health expenditures in aging populations [19]. For low-
and middle-income countries, stepwise approaches to im-
plement prevention activities have high priority to prevent
pre-mature death and to maintain workforce [33, 34].
Taken together, gains in life expectancy, mainly due to
reduction in CVD mortality, have characterized the past
four decades in many industrialized countries, first present
in women then in men. Overall, CVD is still the leading
cause of death worldwide, and most deaths occur in low-
and middle-income countries [30]. Expenditures on health
varied considerably across countries. Although the abso-
lute health expenditure in the US is four times the value
of Singapore, life expectancy in the US lags behind
Singapore by 3 years in women and men. The comparison
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of different health systems may provide further clues for
the effective and successful allocation of resources and
best approaches for healthy ageing. Well-balanced health
politics considering primary and secondary prevention, as
well as individually tailored evidence-based treatment, are
requirements for maintaining or increasing life expectancy.
Conclusions
In most countries life expectancy is increasing. Although
the contribution of different causes of death as well as age
groups changed over time, the overall trend of the life
expectancy development seems to be quite stable. There is
heterogeneity in the achievements to reduce mortality and
improve longevity. For long-lasting improvements in life
expectancy in countries with moderate health expendi-
tures like Japan, the combination of various strategies is
necessary to implement successful and cost-effective pre-
vention programs and to improve social conditions.
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